In our ABT-199 resistance model, we found that the high BCL-xL expression was due to down-regulation of miR-377, an observation similar to what we found in our CLL patients and a panel of lymphoid B-cell lines. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.